MSK Doctors (0330 001 0048), a private specialist clinic in London, has updated its options for Arthrosamid, allowing clients to book their own appointment with no referral, and no waiting list. The clinic has also published an in-depth analysis of related research and cost comparisons.
—
Arthrosamid, a new, single-injection option for knee conditions, is now available from MSK Doctors in London, the first UK clinic approved to provide this new treatment. Clients can schedule an appointment for consultation, diagnosis, or treatment, with one of the MSK Doctors Arthrosamid specialists, to determine if this new treatment is right for them.
More information about scheduling a clinic visit with no referral, how Arthrosamid works, and the research into potential long-term relief from a single treatment can be found at https://mskdoctors.com/treatments/arthrosamid
While knee injections are not new to medicine, Arthrosamid uses a different approach, that specialists believe may allow it to become a permanent part of the client’s knee. Unlike the traditional, bio-degradable knee injections, Arthrosamid is a non-biodegradable hydrogel that cannot easily be absorbed by the body.
Prof. Paul Lee, the founder of MSK Doctors and the clinic’s Arthrosamid specialist, was involved in recent research on the long-term effectiveness of this new treatment. The new paper, A Systematic Review of the Novel Compound Arthrosamid Polyacrylamide (PAAG) Hydrogel for Treatment of Knee Osteoarthritis¹, shows that Arthrosamid continues to provide relief for at least two years, and perhaps longer.
While it is possible for Arthrosamid to provide pain relief for longer, the study was only planned to last for two years. Although researchers have not yet found a maximum duration for the effects of Arthrosamid, the compound has been extensively studied in humans for over 20 years², with only minimal and temporary side effects.
In a new report from MSK Doctors, clients can find an analysis of the costs of Arthrosamid, how they compare to traditional treatments, and several important factors that should be considered. The full report explains that, while the cost can vary based on several factors, it has been considerably reduced compared to traditional treatments, when taking into account the long-term effects.
An excerpt from the full report explains, “Arthrosamid represents a significant stride in managing knee osteoarthritis, offering effective symptom management and long-term benefits. While initial costs may be higher, the cumulative financial and health advantages position it as a prudent investment for many patients. I advocate for a personalised approach, consulting with a specialised orthopaedic surgeon to explore the most appropriate treatment options for individual cases.”
More information about MSK Doctors, Prof. Pau Lee, the no-referral booking system, and the latest cost analysis on Arthrosamid can be found at https://mskdoctors.com/doctors/paul-lee/articles/arthrosamid-treatments-breaking-down-the-costs-and-investment-value
¹ - Overgaard, A. et al., 2019. Clin Ortho Adv Res J.
² - Medical Research Archives, 2022. [Online](https://esmed.org/MRA/mra/article/view/2950)
Contact Info:
Name: Bethan Lee
Email: Send Email
Organization: MSK Doctors
Address: MSK House London Road Silk Willoughby, Sleaford, Lincolnshire, Sleaford, England NG34 8NY, United Kingdom
Website: https://www.mskdoctors.com
Source: PressCable
Release ID: 89125536
Should any errors, concerns, or inconsistencies arise from the content provided in this press release that require attention or if a press release needs to be taken down, we kindly request that you immediately contact us at error@releasecontact.com. Our efficient team will be at your disposal for timely assistance within 8 hours – taking necessary measures to rectify identified issues or providing guidance on the removal process. We prioritize delivering accurate and reliable information.
